Aquestive Therapeutics (AQST) PT Raised to $8 at Lake Street Capital Markets

Lake Street Capital Markets analyst Thomas Flaten raised the price target on Aquestive Therapeutics (NASDAQ: AQST) to $8.00 (from $3.00) while maintaining a Buy rating.

The analsyt commented, "The stage is set for an eventful 2024 with Libervant’s potential April FDA approval and Anaphylm's anticipated NDA submission by year-end, both substantial value generating events. Yesterday, the Company reported 4Q24 revenues of $13.2M, which exceeded our estimate of $11.8M. Affirm Buy and raising PT to $8."

You May Also Be Interested In

• JPMorgan Downgrades ASX Limited (ASX:AU) (ASXFY) to Neutral
• Nomura/Instinet Downgrades Korea Electric Power Corp. (015760:KS) (KEP) to Neutral
• Deutsche Bank Upgrades AutoStore Holdings Ltd (AUTO:NO) to Buy